NewsBenzingaArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients Benzinga 2026.10.25 17:59 (GMT+0) Open on Benzinga Other news Moonshot AI Apologizes for Kimi K3.1 Pro Rate Limiting, Resets 25% Monthly Quota for Subscribers Tesla Is Betting on a Flying Car to Combat Its Stock Slump Third Avenue Real Estate Value Fund Q3 2026 Portfolio Activity Musk: SpaceX Has Completed $40 Billion GPU Debt Financing A $1 Trillion Depreciation Bomb Is Ticking Beneath the AI Market Verizon, Welltower On Deck Monday As Wireless Growth, Senior Housing Demand Face Test
